Skip to main content
CDK4/6 Inhibitors for Treatment of High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Addressing Tolerability to Maximize Treatment Persistence
Read More
Original Research, Adverse Events
Analysis of Ifosfamide-Associated Encephalopathy Between 2 Formulations in Adults With Hematologic Cancer
Karin M. Abernathy, PharmD, BCOP; Colleen McCabe, PharmD, BCOP; Matt Perciavalle, PharmD, BCPS, BCOP; Manuel G. Cortez, PharmD, BCOP; Ryan M. Miller, PharmD, BCOP; Bradley Yelvington, PharmD, BCOP; Vicki L. Keedy, MD, MSCI
Read More
Original Research, Biosimilars
A Survey of Biosimilar Adoption Across Oncology Pharmacy Practices
Marina Reed, PharmD, BCOP; Eugene R. Przespolewski, PharmD, BCOP, DPLA; Mark Walsh, PharmD, BCOP, DPLA; Catherine Forbes, PharmD; Michelle Amsler, PharmD, BCOP; Kristopher Attwood, PhD; Grazyna Riebandt, PharmD, BCOP, DPLA
Read More
Original Research, Adverse Events, Immunotherapy
Evaluation of Serious Immune-Related Adverse Event Incidence in 200-mg Versus 400-mg Pembrolizumab Regimens
Arlet Bacallao Molina, PharmD; Natoya Muirhead, PharmD, BCOP; Erika Rugay, PharmD, BCOP; Karin Thatcher, PharmD, BCPS; Jovino Hernandez, PharmD, BCPS
Read More
Review Article
Azacitidine in Peripheral T-Cell Lymphoma: Prime Time for Epigenetic Modification?
Taylor S. White, PharmD, BCOP; Joseph B. Elmes, PharmD, BCOP; Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP
Read More
The Impact of Underutilizing Adjuvant CDK4/6 Inhibitors in Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Read More
Online First
Original Research, Chemotherapy, Adverse Events
Evaluation of Bleeding Events in Patients Who Received Ibrutinib With or Without Antithrombotic Therapy
Frank A. Lattuca, PharmD, BCOP; Jeremiah E. Moore, PharmD, BCOP; Carissa Treptow, PharmD, BCOP; Kendra Delibert, PharmD, BCOP; Andrea Baran, MS; Clive S. Zent, MD
Read More
Online First
Case Reports, Adverse Events, Antibody–Drug Conjugates , Infusion Issues, Monoclonal Antibodies
Attenuation of Rash From Fam-Trastuzumab Deruxtecan-nxki Via a Desensitization Protocol: A Case Report
Stephanie Budhan, BS; Blanka Kaplan, MD; Grace Kwan-Mangal, PharmD, RPh; Anthony Szema, MD
Read More
Online First
Original Research, Acute Lymphoblastic Leukemia, Anticoagulants, Thromboembolism
Evaluation of Clotting and Bleeding Risk Associated With the Use of Asparaginase Drugs in Patients With Acute Lymphoblastic Leukemia
Alyssa Cendagorta, PharmD, BCOP; Frank Lattuca, PharmD, BCOP; Jeremiah E. Moore, PharmD, BCOP; Kristen O’Dwyer, MD; Andrea Baran, MS; Nicole M. Acquisto, PharmD, FASHP, FCCM, FCCP, BCCCP; Carissa Treptow, PharmD, BCOP
Read More
A Dose Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series
Interview with the Innovators
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
Jamie Carroll, APRN, CNP, MSN
Read More
Page 6 of 197
Results 51 - 60 of 1963